REal-world Clinical evAulation of Medtronic NeurOVascular Products for Acute Ischemic Stroke (RECANOVA Registry)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07599904

Acronym

RECANOVA

Enrollment

1500

Registered

2026-05-20

Start date

2026-07-13

Completion date

2031-07-01

Last updated

2026-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke

Brief summary

Post-Market Registry

Detailed description

An observational, prospective, multi-center, single-arm registry to provide continuing evaluation of safety and effectiveness of Medtronic Neurovascular commercially available products used in the treatment of acute ischemic stroke.

Interventions

DEVICEMechanical Thrombectomy

Index stroke procedure and follow-up visits up to 90 days post index procedure

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patient or legally authorized representative (LAR) provides authorization and/or consent per institution and geographical requirements. 2. Participant is treated or intended to be treated with a commercially available Medtronic Neurovascular device\* during treatment for acute ischemic stroke. 3. Participant is 18 years of age or older.

Exclusion criteria

1. Participant who may be unable to complete follow-up within the registry. 2. Participant of child-bearing potential who is known to be pregnant or is breastfeeding or wishes to become pregnant during participation in the study. 3. Participant is currently enrolled in, or plans to enroll in, any concurrent drug/device study that may confound the study results based on Principal Investigator's discretion.

Design outcomes

Primary

Measure	Time frame	Description
Evaluate device safety	From Day 0 to 90 days post-procedure	Incidence of Safety Events of Interest through 90-day follow-up
Evaluate device performance	Day 0 - end of index stroke procedure	Reperfusion defined as eTICI ≥2b50; ≥2b67; ≥2c; =3 at end of procedure.
Evaluate device effectiveness	From Day 0 to 90 days post-procedure	Functional independence as measured by modified Rankin Scale (mRS) score ≤ 2 at 90-day follow up (mRS scores range from 0 \[no symptoms\] to 6 \[death\]).

Countries

United States

Contacts

CONTACTStephanie Salisbury

rs.recanovaregistry@medtronic.com612-979-7251

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 29, 2026